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PPRECLINICAL STUDIES
Reduced Incidence of Vagally Induced
Atrial Fibrillation and Expression Levels of
Connexins by n-3 Polyunsaturated Fatty Acids in Dogs
Jean-Francois Sarrazin, MD,* Genevieve Comeau, MSC,* Pascal Daleau, PHD,*† John Kingma, PHD,*‡
Isabelle Plante, PHD,* Dominique Fournier, MSC,* Franck Molin, MD*‡
Quebec, Canada
Objectives This open-label canine study assessed whether n-3 polyunsaturated fatty acids (PUFAs) prevent vagally induced
atrial fibrillation (AF) and influence atrial tissue expression levels of connexins (CXs).
Background n-3 polyunsaturated fatty acids in fish oils protect against sudden cardiac death and reduce postoperative AF.
Changes in spatial organization of gap junctions or cellular CX levels have been linked to arrhythmogenesis.
Methods Vagally induced AF was studied. Eight dogs were given fish oil daily for 14 days. Eight control dogs had reproduc-
ibly induced AF and were re-evaluated after intravenous administration of fish oil. Atrial fibrillation was com-
pared, and n-3 PUFA, CX40, and CX43 protein levels were assessed in atrial biopsies.
Results Atrial tissue n-3 PUFA levels increased in oral treatment dogs (5.78  0.71% vs. 2.49  0.46% in control ani-
mals, p  0.001). No difference was observed for atrial refractory periods or hemodynamic or electrocardio-
graphic parameters. Incidence of AF in oral treatment dogs decreased 79% with the extra stimulus technique
(10.5% vs. 48.9%, p  0.003) and 42% with burst induction (22.5% vs. 38.8%, p  0.038). Both CX40 and
CX43 levels were lower in oral treatment dogs (60% [p  0.019] and 42% [p  0.038] lower, respectively); pro-
tection against AF was mostly related to reduced CX40 expression levels (p  0.02). In dogs that were given
intravenous n-3 PUFAs, AF inducibility by the extra stimulus technique was reduced from 75.0% to 28.6% (p 
0.002).
Conclusions Oral treatment with fish oils increased atrial n-3 PUFA levels and reduced vulnerability to induction of AF in this
dog model. Modulation of cardiac CX by n-3 PUFAs probably contributes to the antiarrhythmic effects of fish
oils. (J Am Coll Cardiol 2007;50:1505–12) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.046c
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itrial fibrillation (AF) is a common arrhythmia encoun-
ered in clinical practice. Pharmacotherapy to restore or
aintain normal sinus rhythm is successful in 50% to
0% of patients; many of the drugs used induce important
ide effects and increase risk of ventricular proarrhyth-
ias (1).
See page 1513
Atrial fibrillation is associated with altered electrophysi-
logical properties, mainly reduced atrial effective refractory
eriod (ERP) and slow conduction velocity. The latter
epends on cell-to-cell communications via gap junction
rom the *Institut Universitaire de Cardiologie et Pneumologie, Quebec, Canada;
nd the Faculties of †Pharmacy and ‡Medicine, Laval University, Quebec, Canada.
his study was funded by the QHI Foundation. Ocean Nutrition Canada Ltd.
rovided the fish oil used herein.m
Manuscript received February 14, 2007; revised manuscript received April 30,
007, accepted May 1, 2007.hannels (2). Connexins (CXs) 40, 43, and 45 have been
etected in cardiac tissues; CX40 and CX43 are primary
omponents of atrial gap junctions. Changes in spatial
rganization of gap junctions or cellular levels of cardiac CX
re associated with arrhythmogenesis (2–4); however, their
ole in AF remains controversial. Whether n-3 polyunsat-
rated fatty acids (PUFAs) influence atrial CX content has
ot been investigated. Experimental evidence documents
ntiarrhythmic effects of n-3 PUFAs (5–7); however, few
tudies have focused on treatment with fish oils for atrial
rrhythmias. Increased consumption of fish in patients
ither lowers risk (8), or has no effect on AF (9); n-3 PUFAs
educe postoperative AF (10) and decrease AF burden in
atients with a pacemaker (11).
The present canine study was designed to demonstrate
hat atrial tissue n-3 PUFA levels could be enhanced with
ietary fish oil supplementation thereby leading to reduction
n vagally induced AF. We also examined whether treat-ent with n-3 PUFAs affected expression levels of atrial
n
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Fish Oils Reduce AF and Connexins October 9, 2007:1505–12CX40 and CX43 that could ulti-
mately be associated with re-
duced incidence of AF.
Methods
Experimental design. Adult
mongrel dogs (17 male dogs, 11
female dogs; 18 to 30 kg) were
assigned but not randomized to
either oral treatment with n-3 PU-
FAs or a control group. Dogs were
fed Purina Pro Plan chow (Nestlé
Purina PetCare Company, St.
Louis, Missouri) containing 25%
crude protein, 15% crude fat, 3%
crude fiber, 12% moisture, 1.4%
linoleic acid, 1% calcium, 0.8%
phosphorus, 0.30 mg/kg sele-
ium, and 15,000 IU/kg vitamin A and given water ad
ibitum. Eight dogs were given 1.2 g orally of n-3 PUFAs
320 mg eicosapentaenoic acid [EPA] and 160 mg docosa-
exaenoic acid [DHA] per gram, MEG-3 brand omega-3 fish
il, Ocean Nutrition Canada Ltd., Darmouth, Nova Scotia,
anada) daily for 14 consecutive days. Three dogs were fed
how for 14 days and served as time control animals. Of 17
ontrol dogs, AF was induced by 3 consecutive premature atrial
omplexes (PACs) and burst pacing in 8; these dogs were
e-evaluated after intravenous treatment with fish oil (1.4 g
uspended in carrier solution comprising 10 g of 30%
uman albumin [Sigma Chemical Co., St. Louis, Missouri]
nd saline) infused at 1 ml/min intravenously. This group
erved as its own control as experiments were performed
efore and immediately after fish oil administration.
Baseline hemodynamic parameters including left ventric-
lar end-diastolic pressure and ERP were recorded before
nd during vagal stimulation. Blood was withdrawn for
etermination of serum phospholipid fatty acids levels; a
econd sample was withdrawn from the intravenous treat-
ent group at the end of infusion of n-3 PUFAs (analyzed
y high-performance liquid chromatography, Human Nu-
raceutical Research Unit, University of Guelph, Guelph,
anada). At the end of the experiment but before sacrifice,
large right atrial biopsy was removed for determination of
issue n-3 PUFA and CX40 and CX43 levels.
nimal preparation. Experimental procedures conformed
o guidelines of the Canadian Council on Animal Care
volumes 1 and 2) and were approved by the Laval Univer-
ity Animal Care Committee. Dogs were premedicated with
entanyl (0.02 g/kg subcutaneous) and midazolam (0.1
g/kg intramuscular) and anesthetized with thiopental (20
g/kg intravenous). Fentanyl (5 to 7.5 mg/kg/min intrave-
ous) was continuously infused during the experiment;
nesthesia was maintained using isofluorane (1.5% to 3.5%).
n endotracheal tube was inserted; dogs were ventilated
Abbreviations
and Acronyms
AF  atrial fibrillation
BCL  basic cycle length
CX  connexin
DHA  docosahexaenoic
acid
EPA  eicosapentaenoic
acid
ERP  effective refractory
period
HR  heart rate
PAC  premature atrial
complex
PUFA  polyunsaturated
fatty acidith a positive-pressure respirator (Ohmeda 7800 ventila- vor, DRE Medical Inc., Louisville, Kentucky), and blood
ases were maintained within the physiological range. Body
emperature was kept at 38oC.
A pig-tail catheter was advanced into the left ventricle via
he right femoral artery to measure end-diastolic pressure;
he catheter was subsequently pulled back for measurement
f arterial pressures. A decapolar catheter (DCDA 15S4C4-
0.5, Cordis, Miami Lakes, Florida) was wedged in the
pper right atrium under fluoroscopy and used for atrial
acing and recording of bipolar atrial electrograms. Heparin
150 U/kg intravenous bolus) was given after catheters were
ositioned; half-dose boluses were repeated hourly there-
fter. Surface electrocardiogram, aortic blood pressure, and
ntra-atrial electrical activity were continuously recorded
sing AxoScope software (Axon Instruments, Union City,
alifornia). At the end of the experiment, dogs were given
n overdose of thiopental and sacrificed using euthanyl (107
g/kg intravenous).
agal stimulation and measurement of electrophysiolog-
cal parameters. Vagally induced AF was initiated as pre-
iously described (12,13). After a midline cervical incision,
eft and right vagal nerves were dissected, isolated, and
igated cranially. Teflon-coated stainless steel electrodes
noncoated distal ends) were inserted through an 18-gauge
eedle into each nerve and connected to a Grass stimulator
Astro-Med Inc., West Warwick, Rhode Island) for bilat-
ral vagal stimulation (pulse width of 0.1 ms) that was
nitiated at amplitude of 5 V and frequency of 10 Hz.
mplitude and/or frequency were titrated to lower heart
ate (HR) to 50% baseline values immediately before vagal
timulation (12).
The decapolar catheter was connected to a Ventrix
timulator (Model HV0200, VENTRITEX, Sunnyvale,
alifornia), and pacing and sensing threshold were deter-
ined; pacing was performed at 4 times threshold. Atrial
RP (longest coupling interval between basic drive and
remature impulse that failed to induce atrial depolariza-
ion) was measured using the S1-S2 extra stimulus technique
t basic cycle lengths (BCLs) of 400 ms, 300 ms, 250 ms,
nd 200 ms (13–15). The mean of 3 ERP values at each
CL was used in the data analysis.
F model. Right atrial and vagal stimulations were used to
roduce sustained AF (12,13,15); extra stimulus (14) and
urst pacing (13) were used. For the extra stimulus tech-
ique, a short train of 8 beats at 400 ms (S1) was followed
y 1 (S2), 2 (S3), or 3 (S4) consecutive PACs (Fig. 1).
remature atrial complexes commenced at 10 ms above
RP and were then decreased until AF induction or failure
o capture the signal. Three attempts were made to induce
F for each PAC (S2, S3, and S4). For burst pacing, 30
onsecutive beats were provoked at 100-ms cycle length; 5
ttempts to induce AF were made in each dog. Data were
ecorded independently as either: 1) no AF; 2) nonsustained
F (episodes 1 s but 1 min (15,16); or 3) sustained AF
episodes 1 min). After positive determination of AF,
agal stimulation was stopped. If AF persisted longer than
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October 9, 2007:1505–12 Fish Oils Reduce AF and Connexinsmin, normal sinus rhythm was restored by electrical
ardioversion. Frequency of AF was calculated as the
uotient of the number of successful sustained AF induc-
ions and the total number of attempts for each technique.
rotein isolation and Western blotting for CX40 and
X43. Expression levels of CX40 and CX43 and their
hosphorylated isoforms were measured by Western blot-
ing in biopsies from control dogs (n  8) and dogs treated
rally with n-3 PUFAs (n  7) using a modified technique
rom our laboratory (17).
Total protein content was determined using the Bio-Rad
rotein Assay (Mississauga, Canada) with bovine albumin
s standard and subsequently separated with an 8% dena-
uring–acrylamide gel. Proteins transferred to Immobilon
VDF membranes (Millipore Corp., Mississauga, Canada)
ere incubated (1 h at room temperature) with rabbit
olyclonal antibodies for CX40 and CX43 (epitopes CXA-5
nd -1, Chemicon International, Temecula, California).
ntibodies were diluted in TBS-Tween 1:200 for anti-
X40 and -CX43. Membranes were incubated with a
econdary antibody (anti-rabbit, Cedarlane, Hornby, Can-
da) conjugated with horseradish peroxidase. An enhanced
hemiluminescence detection kit (Amersham Biosciences,
aie d’Urfé, Canada) was used to reveal the antigen-
ntibody complex on Biomax MS Kodak films (Chalon-sur-
aône, France). Images were analyzed using a scanning
ensitometer (ChemiGenius XE, Canberra Packard,
ontreal, Canada). The average densitometric value from
ontrol dogs (n  8) was taken as 100%.
ssessment of atrial omega-3 and -6 levels. Total lipid
Figure 1 Induction of AF
Induction of atrial fibrillation (AF) by the extra stimulus technique. A train of paced
followed by 2 premature atrial complexes, converted sinus rhythm into AF. ECG xtracts were prepared from atrial biopsies by the extraction aethod of Bligh and Dyer (18); lipids were separated by
hin-layer chromatography. Fatty acid methyl esters were
repared from the phospholipids fraction (19) and analyzed
y gas-liquid chromatography with a 60-m DB-23 capillary
olumn (0.32-mm internal diameter).
tatistical analysis. Hemodynamic parameters, electrocar-
iographic measurements, and ERP are reported as mean
tandard deviation. Densitometry values are expressed as
ean  standard error of the mean. A p value 0.05 was
onsidered statistically significant. Between-group com-
arisons were performed using an unpaired Student t test
or the n-3 PUFA oral treatment group and a paired
tudent t test for the intravenous treatment group;
-tailed tests were used for individual statistical compari-
ons. Frequency of sustained AF was compared using Fisher
xact test.
esults
aseline characteristics. Total n-3 PUFA serum levels
ncreased from 2.08  0.41% in control animals to
.17  0.72% (p  0.001) in the oral treatment group;
roportional increases in EPA (0.49% vs. 3.01%) and
HA (0.39% vs. 3.19%) were also observed (Fig. 2).
here was no change in serum levels of n-3 PUFAs in the
ntravenous treatment group: EPA 0.50%, DHA 0.43%,
nd total n-3 PUFAs 2.13%. Atrial tissue n-3 PUFA
evels increased in the oral treatment group (5.78 
.71% vs. 2.49  0.46% in control animals, p  0.001);
mega-6 levels decreased from 48.08  3.15% in control
beats,
cardiogram.atrial
electronimals to 44.55  1.58% (p  0.026) in the oral
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Fish Oils Reduce AF and Connexins October 9, 2007:1505–12reatment group. For the time control group, total n-3
UFA serum levels were 3.37  0.34% and atrial tissue
evels were 2.53  0.34%.
lectrophysiological parameters. Pacing thresholds and
ensing were similar for all groups. During vagal stimula-
ion, HR decreased 46.2% in oral treatment dogs and 45.3%
n control animals (p  NS). Average vagal stimulation
equired to achieve these levels was 11.4 Hz at 6.1 V in the
ral treatment group and 12.9 Hz at 6.1 V in the control
roup (p  NS).
Figure 2 Serum and Atrial Tissue n-3 PUFA Levels
Oral treatment (PO) increased total atrial tissue n-3 polyunsaturated fatty acid
(PUFA) levels, and serum levels of docosahexaenoic acid (DHA), eicosapenta-
enoic acid (EPA), and total n-3 PUFAs (p  0.001).
Hemodynamic and Electrocardiographic Parameand Atrial ERPs at Baseline and During V g l S
Table 1 Hemodynamic and Electrocardiograand Atrial ERPs at Baseline and Du
Control An
Baseline
Blood pressure
Systolic (mm Hg) 108 28
Diastolic (mm Hg) 85 24
End-diastolic pressure (mm Hg) 10 9
ECG
Heart rate (beats/min) 128 13
RR (ms) 474 49
PR (ms) 104 11
QRS (ms) 55 8
QTc (ms) 348 33
ERP at different BCL (ms)
400 133 19
300 122 20
250 113 19
200 105 16BCL  basic cycle length; ECG  electrocardiogram; ERP  effective refractoHemodynamic and electrocardiographic variables were sim-
lar between control and oral treatment groups at baseline and
uring vagal stimulation (Table 1). Vagal stimulation de-
reased blood pressure, prolonged PR interval, and shortened
T interval (p  0.020 for each parameter) in both groups.
ith intravenous treatment, blood pressure was lower, PR
nterval was shorter, and QT interval was longer at baseline;
RS was larger during vagal stimulation (Table 2).
Vagal stimulation shortens atrial ERPs compared with
aseline in all groups (p  0.002), but ERPs were not
ffected by oral or intravenous treatment with n-3 PUFAs
Tables 1 and 2).
F induction. Induction of sustained AF (Fig. 3) using the
xtra stimulus technique had an incidence of AF after 1
AC of 26.0% in control animals (13 of 50 attempts) and
.2% in n-3 PUFA oral treatment dogs (1 of 24 attempts,
 0.019). After 2 PACs, AF was induced in 38.0% of
ontrol animals (19 of 50 attempts) and 12.5% of oral
reatment dogs (3 of 24 attempts, p  0.017). After 3
ACs, AF was 48.9% in control animals (23 of 47 attempts)
nd 10.5% in oral treatment dogs (2 of 19 attempts, p 
.003); these data show a 79% reduction in sustained AF
fter oral treatment with n-3 PUFAs. Combined data for
he extra stimulus technique demonstrated a significantly
ower incidence of AF in oral treatment dogs (37.4% in
ontrol animals vs. 8.9% with oral n-3 PUFAs, p  0.001).
ith burst pacing, sustained AF occurred in 38.8% of
ontrol animals (26 of 67 attempts) and 22.5% of oral
reatment dogs (9 of 40 attempts) (p  0.038).
In the intravenous group, sustained AF with 1 PAC was
4.0% (6 of 25 attempts) versus 33.3% before the infusion
p  NS), 21.1% with 2 PACs (4 of 19 attempts) versus
6.0% in control animals (p  0.017), and 28.6% with 3
ACs (6 of 21 attempts) versus 75.0% before the infusion
p  0.002). With burst pacing, AF occurred in 42.1% of
ation (PO Protocol)
Parameters,
agal Stimulation (PO Protocol)
(n  17) PO (n  8)
Vagal Baseline Vagal
84 20 102 27 85 23
51 17 84 26 58 20
9 6
70 8 119 16 64 11
870 96 512 68 960 156
150 24 115 18 169 34
56 10 58 9 55 11
317 37 339 28 296 22
81 20 128 12 84 21
78 21 115 10 82 18
78 23 106 10 80 17
75 27 102 11 78 17ters,imul
phic
ring V
imalsry period; PO  oral treatment; QTc  corrected QT interval.
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October 9, 2007:1505–12 Fish Oils Reduce AF and Connexinsntravenous treatment dogs (16 of 38 attempts) and 45.0%
efore infusion of n-3 PUFAs (pNS). In the time control
nimals, AF was induced in all dogs; 2 had sustained AFs,
hile the third had nonsustained AF.
Overall, 27 episodes of nonsustained AF (duration
26 s) were induced in control animals; 23 episodes
Hemodynamic and Electrocardiographic Parameand Atrial ERPs at Baseline and During V g l S
Table 2 Hemodynamic and Electrocardiograand Atrial ERPs at Baseline and Du
Pre-IV (n
Baseline
Blood pressure (mm Hg)
Systolic 109 23
Diastolic 86 20
End-diastolic pressure 8 6
ECG
Heart rate (beats/min) 128 12
RR (ms) 472 46
PR (ms) 103 7
QRS (ms) 58 10
QTc (ms) 353 36
ERP at different BCL (ms)
400 135 13
300 125 15
250 116 16
200 107 14
*p  0.035 between preintravenous baseline and intravenous (IV) ba
Abbreviations as in Table 1.
Figure 3 Sustained AF Inducibility
Sustained atrial fibrillation (AF) was reduced from 26.0% to 4.2% with the extra
stimulus technique by 1 premature atrial complex (PAC) in the oral treatment
(PO) group (p  0.019); AF decreased from 38.0% to 12.5% after 2 PACs in
the PO group (p  0.017); AF decreased from 48.9% to 10.5% after 3 PACs in
the PO group (p  0.003); and AF decreased from 38.8% to 22.5% by burst
pacing technique in the PO group (p  0.038).fduration 21 s) were induced in oral treatment dogs (p 
S for episodes and duration); 5 episodes (duration 11 s)
ere induced in intravenous treatment dogs (p  NS).
One control dog developed intractable ventricular tachy-
ardia and was excluded from the data analysis.
estern blotting. Connexin levels were initially ana-
yzed according to treatment group. Atrial CX40 and
X43 levels are shown in Figure 4; in n-3 PUFA oral
reatment dogs, CX40 and CX43 protein levels were 60%
p  0.019) and 42% (p  0.038) lower than those seen
n control animals. In oral treatment dogs, expression
evels of phosphorylated CX40 (P1) decreased by 63%
p  0.024) while the phosphoisoforms of CX43 (P2 and
1) decreased by 49% (p  0.047) and 33% (p  0.153),
espectively. Nonphosphorylated forms of CX40 and
X43 (P0) decreased by 55% (p  0.020) and 43% (p 
.024), respectively.
The CX levels were also compared in control and oral
reatment dogs for which sustained AF was not induced.
he CX43 protein levels were significantly lower with oral
reatment group with regard to the “P0” band (p  0.005)
nd for the total amount of CX43 (p  0.05). For CX40
rotein levels, each of the 2 bands on the Western blot and
he total amount of protein were lower for the oral treat-
ent group (all p  0.02).
Atrial CX levels were compared between dogs with
AF) and without (AF) inducible sustained AF. For
X43, a significant difference (p 0.05) between AF and
F dogs was only obtained in the oral treatment group;
F was associated with lower expression levels of CX43.
ooling results for AF and AF categories for CX43 in
ll treatment groups did not show any significant difference
or phosphorylation state either separately or overall. Dif-
ation (IV Protocol)
Parameters,
agal Stimulation (IV Protocol)
IV (n  8)
Vagal Baseline Vagal
88 14 76 15* 66 11
55 16 48 13* 37 9
67 7 146 25 71 7
06 95 422 72 850 85
43 20 91 8* 126 18
59 12 59 9 66 11
05 27 371 22* 324 29
79 20 145 15 79 20
67 17 124 18 77 18
64 14 114 20 78 16†
61 17 109 22 78 17†
†p  0.035 between pre-IV vagal and IV vagal.ters,imul
phic
ring V
 8)
9
1
3erences in CX40 expression levels were not significant
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Fish Oils Reduce AF and Connexins October 9, 2007:1505–12etween AF and AF dogs for either treatment group
hen considered separately. However, overall differences
ere significant for each of the 2 phosphorylation (p 
.02) states when all AF and AF were respectively
ooled together.
iscussion
ur findings document that oral treatment with n-3 PUFAs
arkedly increases atrial n-3 PUFA tissue levels and lowers
F inducibility in dogs. We also report that oral treatment
ith n-3 PUFAs decreased expression levels of both CX40
nd CX43 in atrial tissues. These findings support recent
ata regarding the antiarrhythmic properties of n-3 PUFAs
8,10).
issue levels of n-3 PUFAs. Blood and atrial tissue n-3
UFA levels were significantly augmented in dogs given
sh oils over 14 days. To evaluate the influence of the
tandard diet in the oral treatment group, 3 dogs were
tudied after 14 days of standard chow. Total serum n-3
UFA levels were higher compared with those in control
nimals (3.37  0.34% vs. 2.08  0.41%) but were much
ower than values for the oral treatment group. Nonetheless,
trial tissue levels of either n-3 or n-6 PUFAs were not
ifferent in time control group compared with those in the
nitial control group (2.53  0.34% vs. 2.49  0.46%, and
8.36  0.75% vs. 48.08  3.15%). The relation between
lood and cardiac fatty acid composition needs further
nvestigation, but recent clinical (20) and experimental (21)
ndings show that red cell EPA  DHA levels may be the
Figure 4 Western Blots for CX in Atrial Tissues
Representative Western blots for connexin (CX)40 (A) and CX43 (B) in atrial tissu
tested in duplicate. (C and D) Mean  standard error of the mean for CX40 and C
ations as in Figure 2.referred surrogate for cardiac omega-3 status. The dose of h-3 PUFAs (1.2 g daily of EPADHA) used in this study
as comparable to recommendations of the American
eart Association (22), and was sufficient to reach thera-
eutic levels. Dietary intake and associated elevated blood
evels of n-3 PUFAs have been associated with reduced risk
f sudden cardiac death (23,24).
lectrophysiological properties. Atrial refractoriness was
ot affected in fish oil-fed dogs compared with that seen
n control dogs. These data are not consistent with
ndings from isolated rabbit hearts undergoing rapid
urst pacing and increasing intra-atrial pressures (21).
ifferences could be due to different experimental models
nd variations of action potential characteristics in higher
ammalian species. Electrophysiological findings in our
tudy concord with recent reports of reduced AF after n-3
UFA treatment (8,10,11). The mechanisms responsible
or these antiarrhythmic effects remain unclear but are
ot related to cardiac hemodynamics or atrial ERP. The
-3 PUFA may prevent ventricular arrhythmias by in-
ibiting fast, voltage-dependent sodium channels and
-type calcium channels (21,25). QRS and QTc dura-
ions were not statistically different in oral treatment dogs
uggesting that these channels are not altered in situ;
owever, the present study is underpowered to confirm
his hypothesis. In comparison with the oral treatment
roup, PR interval was shorter and QT longer in the
ntravenous group, but the ERPs were not different.
hese findings are not consistent with a previous study
5) where there were no changes. Earlier animal and
control animals and n-3 PUFA PO dogs. All protein expression levels were
n  8 for control animals and n  7 for n-3 PUFA PO dogs). p  0.05. Abbrevi-es from
X43 (uman studies using standard doses of n-3 PUFAs did
n
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October 9, 2007:1505–12 Fish Oils Reduce AF and Connexinsot detect differences in electrocardiographic parameters
5,26). Modulation of conduction velocity or conduction
eterogeneity was not addressed in the present study.
ardiac CXs and n-3 PUFAs. An association between
F, increased CX expression, and remodeling of gap
unction distribution has been documented (3,27,28).
hronic atrial pacing increases CX43 expression in dogs
27) and is associated with depressed atrial conduction. This
aradox may be reconciled by altered distribution patterns of
ap junctions (i.e., changed anisotropy) that contribute to
evelopment of multiple wavelet re-entry. Increased CX40
xpression has been associated with higher AF susceptibility
n patients (4). However, no change or decreased CX40 and
X43 expression has been reported in a goat model of AF
29). In heterozygous CX43/ knockout mice, no differ-
nce in atrial conduction was observed compared with that
n wild type (30); during myocardial infarction, frequency of
pontaneous or inducible arrhythmias compared with that in
ild type did not increase, indicating that reduced CX43
xpression is not related to arrhythmogenicity (31).
In the present study, lower cardiac CX40 and CX43 levels
fter oral n-3 PUFA treatment were associated with an
ncreased AF triggering threshold. Connexin levels in con-
rol and oral treatment dogs were compared in only those
nimals in which sustained AF was not induced. Lower
X40 and CX43 levels were observed in treated dogs
uggesting that AF, per se, did not impact on differences in
X expression levels. Comparison of CX levels between
F and AF dogs indicated that AF was associated
ith lower CX43 expression levels in only the oral treatment
roup. Differences in CX40 expression levels were signifi-
ant overall and for both phosphorylation states when AF
nd AF data were respectively pooled. As such, protection
gainst AF was mostly related to reduced CX40 expression
evels.
The CX phosphorylation is associated with either in-
reased or decreased gap junction intercellular communica-
ions (32,33); poor correlation between cell-to-cell commu-
ication and changes in CX43 phosphorylation status has
een reported (34). We did not observe major changes in
he ratio of phosphorylated and nonphosphorylated forms
f CX40 and CX43 in association with the lower CX40 and
X43 expression levels; further experiments are necessary to
lucidate mechanisms involved in n-3 PUFA-induced
own-regulation of these 2 cardiac CXs.
otential limitations. Atrial fibrillation is a progressive
nd slowly evolving condition in humans; therefore, data
rom short-term studies should be interpreted with caution.
hile vagal stimulation facilitates induction of prolonged
F (12–14,16), the latter was only induced in 50% of
ontrol animals. Further limitations include: 1) autonomic
one influences AF (35), but vagally mediated paroxysmal
F is uncommon in humans (36); 2) AF usually occurs in
iseased atria; 3) AF induced by vagal stimulation in dogs
iffers significantly from that observed in humans; and 4)
he present study lacks randomization and blinding.Results for the intravenous treatment group are difficult
o interpret. Absence of change in serum n-3 PUFA levels
ay be due to the rapid blood clearance of n-3 PUFAs (i.e.,
10% to 15% by 5 min, dropping to 1% to 2% by 25 min)
37); it may also be related to the lower dose of n-3 PUFAs
dministered compared with dosages used in earlier studies
38). The lower incidence of AF in these dogs during 2 or
PACs might be due to indirect actions of n-3 PUFAs
espite normal plasma levels or by unknown effects of
lbumin.
onclusions
ral treatment with fish oils markedly increased serum and
trial tissue n-3 PUFA levels and reduced vulnerability to
nduction of AF. Modulation of cardiac CX probably
ontributes to the antiarrhythmic effects of fish oil supple-
entation. These findings add further insight to mecha-
isms involved in atrial arrhythmogenic remodeling and
upport the rationale for continued clinical studies to exam-
ne cardioprotective effects of dietary fish oil supplementa-
ion in man.
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